Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 07 03:51PM ET
2.61
Dollar change
-0.10
Percentage change
-3.52
%
IndexRUT P/E- EPS (ttm)-1.61 Insider Own34.69% Shs Outstand167.13M Perf Week-6.96%
Market Cap544.73M Forward P/E- EPS next Y-1.49 Insider Trans2.39% Shs Float136.57M Perf Month8.09%
Income-278.45M PEG- EPS next Q-0.33 Inst Own66.85% Short Float28.69% Perf Quarter13.26%
Sales0.09M P/S6052.57 EPS this Y32.39% Inst Trans29.69% Short Ratio18.24 Perf Half Y-34.55%
Book/sh2.46 P/B1.06 EPS next Y-5.29% ROA-39.28% Short Interest39.19M Perf Year-17.30%
Cash/sh2.13 P/C1.23 EPS next 5Y1.00% ROE-48.94% 52W Range2.01 - 5.78 Perf YTD-18.85%
Dividend Est.- P/FCF- EPS past 5Y22.18% ROI-46.25% 52W High-54.89% Beta0.83
Dividend TTM- Quick Ratio12.25 Sales past 5Y-27.79% Gross Margin-16467.44% 52W Low29.60% ATR (14)0.20
Dividend Ex-Date- Current Ratio12.25 EPS Y/Y TTM34.36% Oper. Margin-314866.28% RSI (14)47.07 Volatility7.95% 8.07%
Employees233 Debt/Eq0.18 Sales Y/Y TTM-24.70% Profit Margin-323780.23% Recom1.61 Target Price9.34
Option/ShortYes / Yes LT Debt/Eq0.17 EPS Q/Q34.27% Payout- Rel Volume0.36 Prev Close2.70
Sales Surprise-99.92% EPS Surprise0.00% Sales Q/Q-100.00% EarningsAug 07 AMC Avg Volume2.15M Price2.61
SMA20-5.22% SMA50-1.69% SMA200-19.33% Trades Volume764,062 Change-3.52%
Date Action Analyst Rating Change Price Target Change
Aug-08-24Resumed Oppenheimer Outperform $13 → $11
May-31-24Initiated Piper Sandler Overweight $11
Jan-05-24Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jan-05-24Downgrade Guggenheim Buy → Neutral
Dec-08-23Initiated Citigroup Buy $7
Dec-08-23Initiated Citigroup Buy
Jun-26-23Resumed Oppenheimer Outperform $28
Mar-21-23Initiated Bernstein Mkt Perform $6
Jan-24-23Upgrade JP Morgan Neutral → Overweight $20 → $11
Jan-06-23Upgrade Robert W. Baird Neutral → Outperform $12
Oct-03-24 07:19AM
Sep-30-24 08:30AM
Sep-26-24 08:30AM
Sep-14-24 05:39PM
Sep-06-24 11:31AM
09:50AM Loading…
Aug-08-24 09:50AM
08:30AM
06:00AM
Aug-07-24 04:10PM
04:02PM
Jul-31-24 08:30AM
Jul-01-24 08:30AM
Jun-27-24 10:13AM
Jun-26-24 04:36PM
Jun-20-24 08:30AM
11:30AM Loading…
Jun-12-24 11:30AM
May-29-24 08:55AM
May-28-24 04:05PM
May-23-24 08:30AM
May-21-24 01:56PM
08:16AM
May-16-24 08:13AM
May-14-24 12:56PM
09:14AM
08:21AM
03:06AM
May-13-24 08:55PM
05:36PM
05:10PM
04:47PM
04:17PM Loading…
04:17PM
04:14PM
04:01PM
May-06-24 08:30AM
Apr-26-24 10:32AM
08:30AM
Apr-24-24 10:01AM
Apr-11-24 02:45PM
Apr-09-24 08:30AM
Apr-08-24 08:46AM
Mar-16-24 04:35PM
Mar-15-24 09:32AM
07:04AM
Mar-14-24 08:55PM
05:34PM
05:15PM
04:15PM
04:05PM
Mar-13-24 12:15PM
Mar-12-24 08:50AM
08:30AM
Mar-05-24 09:55AM
08:30AM
Feb-28-24 08:30AM
Feb-16-24 08:30AM
Jan-16-24 04:05PM
Jan-12-24 08:34AM
Jan-05-24 12:52PM
08:25AM
08:13AM
Jan-04-24 04:15PM
04:05PM
11:05AM
Jan-03-24 04:05PM
Dec-09-23 12:00PM
Dec-01-23 08:30AM
Nov-24-23 06:40AM
Nov-10-23 12:00PM
Nov-03-23 12:15PM
12:00PM
12:00PM
10:15AM
Nov-02-23 07:33PM
04:12PM
04:02PM
09:00AM
Oct-30-23 08:30AM
Oct-26-23 08:30AM
Oct-16-23 09:26AM
08:30AM
Sep-27-23 09:09AM
Sep-25-23 08:45AM
Sep-05-23 08:30AM
Aug-29-23 07:30AM
Aug-23-23 12:26PM
Aug-17-23 08:44AM
Aug-14-23 08:30AM
Aug-03-23 11:20AM
Aug-02-23 05:25PM
04:13PM
04:02PM
10:41AM
Jul-26-23 08:30AM
Jun-15-23 09:30AM
Jun-14-23 08:00AM
Jun-09-23 06:25PM
08:02AM
Jun-03-23 09:00AM
Jun-02-23 11:31AM
May-31-23 12:02PM
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Douglas Earl MartinOfficerAug 21 '24Proposed Sale2.7928,31078,844Aug 21 04:18 PM
MESSEMER DEBORAH M.DirectorJun 18 '24Sale2.2818,64142,488166,765Jun 20 04:31 PM
Humer Franz BDirectorMay 30 '24Sale2.3411,20026,181255,253Jun 03 04:09 PM
Belldegrun ArieDirectorMay 16 '24Buy2.901,724,1374,999,9971,724,137May 20 09:33 PM
Parker Geoffrey M.CHIEF FINANCIAL OFFICERJan 30 '24Buy3.60190683819,590Mar 06 09:52 PM
MESSEMER DEBORAH M.DirectorDec 18 '23Sale2.7018,64050,31762,456Dec 20 04:26 PM